Polyneuron announces the completion of a CHF 3.1 million seed financing, following the receipt of a second tranche. Furthermore, the company’s management team and the board of directors have been strengthened. Press release
In other news
-
Uncategorized
We are extremely pleased to welcome Aled Williams to Polyneuron… [read on]
Polyneuron appoints Aled Williams as chief business officer -
General
Polyneuron announces a CHF 14 million extension of the Series… [read on]
Polyneuron extends Series A to CHF 36.5 million -
General
Polyneuron is proud to announce that the U.S. Food and… [read on]
Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy -
General
We are very proud to have received our… [read on]
Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathy -
General
We are extremely pleased to welcome Dr Debra Barker to… [read on]
Polyneuron announces appointment of chief medical officer -
General
Polyneuron announces the appointment of Ben Machielse as Chairman of… [read on]
Polyneuron annouces appointment of new Chairman -
Financing
Polyneuron raises CHF 22.5 million in an oversubscribed… [read on]
Polyneuron raises CHF 22.5 million in a major Series A financing -
Awards
After a first grant of CHF 10’000 during Phase… [read on]
Polyneuron supported by BaseLaunch Accelerator -
Awards
Polyneuron was selected into phase I of the new BaseLaunch… [read on]
Polyneuron participates in BaseLaunch Accelerator -
General
Polyneuron has obtained the orphan drug designation from the European… [read on]
EMA Orphan Drug Designation for PN-1007 -
General
Polyneuron publishes top PN-1007 in vivo data in the renowned… [read on]
PN-1007 article published in PNAS -
Awards
Polyneuron is proud to announce that it has obtained the… [read on]
CTI Start-up Label